Biotech stocks have tumbled in recent months and years. For example, the SPDR S&P Biotech ETF (NYSE:XBI) has sunk 40% so far this year. As a result, there are many oversold biotech stocks for investors to buy.
But in the next six months, two main factors should push the sector much higher.
Here are three oversold biotech stocks that are well-positioned to benefit from this improved environment.
The post 3 Oversold Biotech Stocks to Buy Now appeared first on InvestorPlace.